IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 250 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $317,667 | +29.7% | 69,817 | +100.7% | 0.01% | +37.5% |
| Q2 2023 | $244,929 | +15.2% | 34,791 | 0.0% | 0.01% | +14.3% |
| Q1 2023 | $212,573 | -4.4% | 34,791 | 0.0% | 0.01% | -12.5% |
| Q4 2022 | $222,314 | -33.2% | 34,791 | 0.0% | 0.01% | -33.3% |
| Q3 2022 | $333,000 | -56.6% | 34,791 | -50.0% | 0.01% | -14.3% |
| Q2 2022 | $768,000 | +32.6% | 69,582 | +100.0% | 0.01% | -22.2% |
| Q1 2022 | $579,000 | +10.9% | 34,791 | +27.3% | 0.02% | +12.5% |
| Q4 2021 | $522,000 | -22.6% | 27,338 | 0.0% | 0.02% | -27.3% |
| Q3 2021 | $674,000 | -5.2% | 27,338 | 0.0% | 0.02% | -8.3% |
| Q2 2021 | $711,000 | -17.9% | 27,338 | 0.0% | 0.02% | -25.0% |
| Q1 2021 | $866,000 | -31.7% | 27,338 | 0.0% | 0.03% | -30.4% |
| Q4 2020 | $1,268,000 | +40.9% | 27,338 | 0.0% | 0.05% | +17.9% |
| Q3 2020 | $900,000 | +6.4% | 27,338 | -11.3% | 0.04% | +5.4% |
| Q2 2020 | $846,000 | -7.8% | 30,806 | +0.4% | 0.04% | -15.9% |
| Q1 2020 | $918,000 | +8.0% | 30,681 | -0.0% | 0.04% | +83.3% |
| Q4 2019 | $850,000 | +85.2% | 30,693 | +21.8% | 0.02% | +100.0% |
| Q3 2019 | $459,000 | – | 25,206 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |